Primary Open Angle Glaucoma Clinical Trial
Official title:
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
Verified date | November 2022 |
Source | Sanoculis Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.
Status | Completed |
Enrollment | 96 |
Est. completion date | December 15, 2020 |
Est. primary completion date | January 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - End Stage primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma in the study eye (EGS criteria) - Optic nerve appearance characteristic of glaucoma in the study eye - Best-corrected visual acuity (BCVA) of counting-fingers, hand movements, light perception or no light perception due to glaucomatous loss of central vision in the study eye - Patient is treated with 1 to 5 hypotensive medications in the study eye - Unsatisfactory medicated IOP (= 18 mmHg) at the screening visit in the study eye - Shaffer grade = III in all four angle quadrants in the study eye - Subject is able and willing to attend all scheduled follow-up exams - Subject understands and signs the informed consent Exclusion Criteria: - Subjects presenting 1 or more of the following criteria will not be enrolled in the trial: - Ocular conditions with a poorer prognosis in the fellow eye than in the study eye - Closed angle forms of glaucoma in either eye - Congenital or developmental glaucoma in either eye - Other secondary glaucoma (such as neovascular, uveitic, lens-induced, trauma-induced, or glaucoma associated with increased episcleral venous pressure) in the study eye - Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the study eye - Subject has history of penetrating keratoplasty (PKP) - Any previous surgery in the study eye (except for clear corneal cataract surgery) where the conjunctiva is not intact and elastic. - Any ocular disease or history in study eye such as severe dry eye, active proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and ocular pathology that may interfere with accurate IOP measurements - Prior surgery for an ab-interno or ab-externo device implanted in or through the Schlemm's canal in the study eye. - Use of oral hypotensive medication for glaucoma for treatment of the fellow eye - Less than the minimum visual function required for driving in the fellow eye: best-corrected visual acuity worse than 20/40 (Snellen equivalent) or Esterman visual field score less than 85%. - History of idiopathic or autoimmune uveitis in either eye - Severe trauma in study eye - active iris neovascularization, previous cyclodestructive procedure, prior scleral buckling procedure, presence of silicone oil, need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery in study eye within 12 month period - Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in study eye - Aphakia - Prior vitreoretinal surgery in study eye - Clinically significant ocular inflammation or infection within 90 days prior to screening - Unable to discontinue use of blood thinners in accordance with surgeon's standard preoperative instructions - Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits - Current participation or participation in another investigational drug or device clinical trial within the last 30 days before screening visit - Pregnant or lactating women |
Country | Name | City | State |
---|---|---|---|
Israel | Goldschleger Eye Institute, The Chaim Sheba Medical Center | Tel Hashomer |
Lead Sponsor | Collaborator |
---|---|
Sanoculis Ltd |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall incidence of serious adverse events | 12 weeks | ||
Secondary | Incidence of serious adverse events | 24 weeks | ||
Secondary | intraocular pressure (IOP) between 6 mmHg and 15 mmHg without medication | 24 weeks | ||
Secondary | Change in number of glaucoma medications from baseline in the study eye | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05564091 -
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
|
N/A | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01384149 -
EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA
|
Phase 1 | |
Completed |
NCT00300079 -
Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
|
Phase 4 | |
Enrolling by invitation |
NCT00221923 -
African Descent and Glaucoma Evaluation Study
|
||
Recruiting |
NCT05605743 -
Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure
|
N/A | |
Completed |
NCT04828057 -
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
|
||
Completed |
NCT01442896 -
STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
|
||
Enrolling by invitation |
NCT05557721 -
Uddevalla Skövde Transscleral Micropulse Study
|
||
Recruiting |
NCT04595227 -
Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
|
||
Terminated |
NCT04141865 -
Effect of Xen Implantation on the Aqueous Humor Proteome
|
||
Completed |
NCT01943721 -
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
|
Phase 1 | |
Completed |
NCT01979913 -
An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More
|
Phase 4 | |
Not yet recruiting |
NCT01711177 -
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT01769521 -
Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG
|
N/A | |
Completed |
NCT02023242 -
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
|
N/A | |
Recruiting |
NCT00773877 -
Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients
|
N/A | |
Recruiting |
NCT00773123 -
Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.
|
N/A | |
Completed |
NCT02544646 -
Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG
|
N/A |